Back |
home / stock / bgne / bgne message board
Subject | By | Source | When |
---|---|---|---|
BGNE presently $269.42 +$6.19 (+2.35%) | MiamiGent | investorshub | 01/13/2023 7:42:57 PM |
znewcar1: $BGNE 20% v854K c151.3 f103,7M H155.74 ML124.46 | znewcar1 | investorshangout | 10/12/2022 8:50:54 PM |
Looking good! | luke424 | investorshub | 05/05/2022 6:43:44 PM |
Last year, I think Bernstein had price target | luke424 | investorshub | 04/01/2022 1:44:56 PM |
Great, Old timers will soon begin loading up | luke424 | investorshub | 04/01/2022 1:27:07 PM |
Made a nice bet. Bought yesterday. https://www.cnbc.com/2022/04/01/china-securit | luke424 | investorshub | 04/01/2022 1:20:06 PM |
$AMGN to acquire 20% stake in BGNE; joint | north40000 | investorshub | 11/04/2019 1:57:31 AM |
Market sentiment is not good for pharmaceutical company, | StockLearner2011 | investorshub | 03/26/2019 6:46:50 PM |
Hope no one will jump down the window | StockLearner2011 | investorshub | 03/26/2019 4:20:57 PM |
Buy out is not going to happen that | StockLearner2011 | investorshub | 03/22/2019 7:24:38 PM |
Looking at insider transactions, the total shares bought | StockLearner2011 | investorshub | 03/22/2019 7:22:16 PM |
Howard Liang could have made 40000 X $22 | StockLearner2011 | investorshub | 03/22/2018 12:03:58 PM |
https://www.gurufocus.com/news/648598/beigene-ltd-bgne-ceo-john-oyler-sold-144-m | StockLearner2011 | investorshub | 03/22/2018 10:51:09 AM |
https://stocknewstimes.com/2018/03/21/beigene-ltd-bgne-cfo-howard-liang-sells-10 | StockLearner2011 | investorshub | 03/21/2018 5:15:40 PM |
https://finviz.com/quote.ashx?t=Bgne The chart looks traight shooting up! | StockLearner2011 | investorshub | 03/21/2018 3:23:25 PM |
Strong buy! | StockLearner2011 | investorshub | 03/21/2018 12:08:45 PM |
Hot stock. It's looking strong! | StockLearner2011 | investorshub | 03/20/2018 3:34:57 PM |
BeiGene Announces Approval of REVLIMID for Newly Diagnosed | SweepsMcGee | investorshub | 02/27/2018 11:28:18 PM |
$BGNE: New message board for a Chinese biotech | north40000 | investorshub | 02/25/2018 9:18:39 PM |
News, Short Squeeze, Breakout and More Instantly...
Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutation Preliminary data suggest promising efficacy and tolerability Safety profile was consistent with results o...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclude their partnership. This strategic decision aligns with BeiGene’s goals to expand its presence and directly manage operations in the MENA region. T...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 with a fireside chat at 1:20 pm EDT. Live webcast of this event can be acce...